April 08, 2019 | FAH Policy Blog Team
FAH sent a letter to the House Ways and Means Committee Chairman Richard Neal (D-MA) and Ranking Member Kevin Brady (R-TX) in support of the Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act.
In the letter, FAH applauds the Committee’s bipartisan effort to address the rising cost of prescription drugs, calling the legislation an “important step in beginning to find solutions to lower prescription drug costs for patients.” The STAR Act seeks to provide price transparency by requiring certain drug manufacturers to report on product samples provided to particular health care providers.
FAH also highlighted in the letter the recent drug pricing study we released along with the American Hospital Association (AHA) and the American Society of Health-System Pharmacists (ASHP). It detailed how continued rising drug prices, as well as shortages for many critical medications, are impacting patient care and putting strains on hospital budgets and operations. According to the study, the average total drug spending per hospital admission increased by 18.5% between FY2015 and FY2017.
To read FAH’s full support letter click here.
- Public Charge Rule Could Have Chilling Effect on Access to Care
- REPORT: A Medicare Public Option Puts Majority of Rural Hospitals at Risk
- In the News – FAH’s Study on Modernizing the HCAHPS Patient Experience Survey
- Joint Statement from National Hospitals Associations on Proposed CY 2020 OPPS Rule